CHICAGO — In this Healio Video Perspective, Carl D. Regillo, MD, discusses 3-year follow-up data from the Archway study presented during Retina Subspecialty Day at the AAO meeting.
The Archway study investigated the Port Delivery System with ranibizumab, now called Susvimo (Genentech), for the treatment of wet age-related macular degeneration. It showed positive safety and efficacy results in patients who underwent 3 years of follow-up as well as those who underwent 1 year of follow-up in addition to previous intravitreal injections, according to Regillo.